1[1]Robert M J, Payam N, Philip C H.Lalent Tuberculo sis lnfection.The New England Journal of Medicine,2002,347:1860～1866 被引量：1
2[2]Kushigemachi M, Schneiderman L J,Barrett connor E.Racial difference in susceptibility to tuberculosis:Risk of disease after infection.J chronic Dis,1984,37:853～862 被引量：1
3[3]RE Watkins,R Brennan,A J Plant.Tubecu linreactivity and the risk of tuberculosis: a review INT J TUBERC LUNG.Dis,2000,4:895～903 被引量：1
4[4]IUAT Committee on Prophylaxis. Efficacy of various duration of isonijid prevetive therapy to tuberculosis:five Years of follow up in the IUAT trial.Bull WHO,1982,60:555～564 被引量：1
5[5]Ferebees H.Controlled chemopropylaxis trials in tuberculosis :a general review.Advances in tuberculosis,1969,17～25 被引量：1
6[7]Hong Kong chest Service/Tuberculosis Research Centre, British Medical Research Council.A double-blind placebo-controlled clinical of three anti tuberculosis chemoprophylaxia regimens in patients with silicosis in Hong Kong.Am Rew Respir Dis,1992,145:36～41 被引量：1
7[8]Update: Adverse Eyent Data and Revised American Thoracic Society/CDC Recommen dations Against the Use of Rifampin and Pyrajinamide for Treatment of Latent Tuberculosis In fection-United States.2003MMWR,2003,52:735～739 被引量：1
8[9]Enarson DA,Rieder HL, Arna dottir T,et al.Mangement of tuberculosis.A guide for low in come countries. 5 ed.Paris: IUATLD,2000,81～89 被引量：1
